A Norwegian man has been free of the virus for nearly two and a half years following treatment and is likely cured of HIV.

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

BEEHIVE follows individuals enrolled in eight cohorts across Europe and Uganda to understand better the molecular basis of HIV strains and which mutations in HIV's genetic sequence are associated ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B ...

However, the optimal means of interpreting these sequences is not known. HIV-SEQ identifies mutations and helps in their interpretation, but does not have the logical or heuristic power to provide ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Thus, HIV mutation and recombination have a great impact on therapy and vaccine design. I remain to be convinced, however, that the emphasis of vaccine design on the basis of clades is HIV science.

Swanson et al, An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations, Science Translational Medicine (2025).

An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...